Loading...

Centogene N.V.

CNTGNASDAQ
Healthcare
Medical - Diagnostics & Research
$0.33
$0.00(0.00%)

Centogene N.V. (CNTG) Stock Overview

Explore Centogene N.V.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 63.4/100

Key Financials

Market Cap9.4M
P/E Ratio-0.22
EPS (TTM)$-1.39
ROE3.98%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.08

CNTG Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Centogene N.V. (CNTG) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.08.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.22 and a market capitalization of 9.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for CNTGStats details for CNTG are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for CNTGAnalyst Recommendations details for CNTG are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including PCR and antigen testing services. It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.

CEO

Kim Stratton

Employees

384

Headquarters

Am Strande 7, Rostock

Founded

2019

Frequently Asked Questions

;